Bank of America’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.85M | Sell |
170,013
-172,940
| -50% | -$2.16M | ﹤0.01% | 4167 |
|
|
2025
Q4 | $4.43M | Buy |
342,953
+10,482
| +3% | +$135K | ﹤0.01% | 3484 |
|
|
2025
Q3 | $4.3M | Sell |
332,471
-60,622
| -15% | -$810K | ﹤0.01% | 4157 |
|
|
2025
Q2 | $7M | Buy |
393,093
+156,834
| +66% | +$2.73M | ﹤0.01% | 3557 |
|
|
2025
Q1 | $4.21M | Buy |
236,259
+157,591
| +200% | +$3.58M | ﹤0.01% | 3994 |
|
|
2024
Q4 | $2.34M | Sell |
78,668
-425,188
| -84% | -$9M | ﹤0.01% | 4320 |
|
|
2024
Q3 | $7.88M | Sell |
503,856
-47,780
| -9% | -$866K | ﹤0.01% | 3295 |
|
|
2024
Q2 | $9.45M | Sell |
551,636
-703,495
| -56% | -$12.4M | ﹤0.01% | 3002 |
|
|
2024
Q1 | $19.6M | Buy |
1,255,131
+576,519
| +85% | +$8.48M | ﹤0.01% | 2303 |
|
|
2023
Q4 | $10.1M | Buy |
678,612
+509,429
| +301% | +$6.82M | ﹤0.01% | 2879 |
|
|
2023
Q3 | $2.73M | Buy |
169,183
+43,768
| +35% | +$1.26M | ﹤0.01% | 3969 |
|
|
2023
Q2 | $5.2M | Sell |
125,415
-228,364
| -65% | -$14.2M | ﹤0.01% | 3360 |
|
|
2023
Q1 | $21.3M | Buy |
353,779
+175,581
| +99% | +$14M | ﹤0.01% | 2068 |
|
|
2022
Q4 | $13.1M | Sell |
178,198
-63,260
| -26% | -$4.76M | ﹤0.01% | 2425 |
|
|
2022
Q3 | $18.3M | Buy |
241,458
+72,524
| +43% | +$5.66M | ﹤0.01% | 2042 |
|
|
2022
Q2 | $11.7M | Sell |
168,934
-30,660
| -15% | -$2.31M | ﹤0.01% | 2525 |
|
|
2022
Q1 | $16.5M | Sell |
199,594
-10,982
| -5% | -$809K | ﹤0.01% | 2334 |
|
|
2021
Q4 | $15.8M | Sell |
210,576
-22,164
| -10% | -$2.22M | ﹤0.01% | 2449 |
|
|
2021
Q3 | $27M | Buy |
232,740
+69,013
| +42% | +$10.4M | ﹤0.01% | 1896 |
|
|
2021
Q2 | $36.3M | Sell |
163,727
-32,860
| -17% | -$6.39M | ﹤0.01% | 1600 |
|
|
2021
Q1 | $26M | Sell |
196,587
-4,893
| -2% | -$774K | ﹤0.01% | 1810 |
|
|
2020
Q4 | $34.9M | Buy |
201,480
+12,696
| +7% | +$1.74M | ﹤0.01% | 1436 |
|
|
2020
Q3 | $21M | Buy |
188,784
+18,870
| +11% | +$1.51M | ﹤0.01% | 1664 |
|
|
2020
Q2 | $10.1M | Sell |
169,914
-62,197
| -27% | -$4.09M | ﹤0.01% | 2207 |
|
|
2020
Q1 | $15.6M | Buy |
232,111
+113,249
| +95% | +$8.95M | ﹤0.01% | 1699 |
|
|
2019
Q4 | $10M | Sell |
118,862
-18,961
| -14% | -$1.53M | ﹤0.01% | 2554 |
|
|
2019
Q3 | $10.3M | Buy |
137,823
+55,375
| +67% | +$4.43M | ﹤0.01% | 2484 |
|
|
2019
Q2 | $5.21M | Sell |
82,448
-42,067
| -34% | -$2.13M | ﹤0.01% | 3195 |
|
|
2019
Q1 | $6M | Buy |
124,515
+63,858
| +105% | +$3.07M | ﹤0.01% | 2994 |
|
|
2018
Q4 | $2.03M | Buy |
60,657
+11,378
| +23% | +$416K | ﹤0.01% | 3835 |
|
|
2018
Q3 | $2.58M | Sell |
49,279
-43,791
| -47% | -$1.74M | ﹤0.01% | 3778 |
|
|
2018
Q2 | $2.91M | Sell |
93,070
-265,343
| -74% | -$7.38M | ﹤0.01% | 3667 |
|
|
2018
Q1 | $7.81M | Buy |
358,413
+270,778
| +309% | +$5.82M | ﹤0.01% | 2653 |
|
|
2017
Q4 | $1.77M | Buy |
87,635
+36,494
| +71% | +$703K | ﹤0.01% | 4063 |
|
|
2017
Q3 | $1.01M | Buy |
51,141
+19,278
| +61% | +$379K | ﹤0.01% | 4495 |
|
|
2017
Q2 | $552K | Sell |
31,863
-5,668
| -15% | -$73.2K | ﹤0.01% | 4834 |
|
|
2017
Q1 | $305K | Buy |
37,531
+14,321
| +62% | +$103K | ﹤0.01% | 5127 |
|
|
2016
Q4 | $182K | Buy |
23,210
+11,692
| +102% | +$94K | ﹤0.01% | 5363 |
|
|
2016
Q3 | $98K | Sell |
11,518
-1,714
| -13% | -$15.6K | ﹤0.01% | 5445 |
|
|
2016
Q2 | $155K | Buy |
13,232
+12,911
| +4,022% | +$162K | ﹤0.01% | 5331 |
|
|
2016
Q1 | $5K | Sell |
321
-638
| -67% | -$9.15K | ﹤0.01% | 6572 |
|
|
2015
Q4 | $21K | Buy |
+959
| New | +$22.9K | ﹤0.01% | 6402 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Bank of America's NVCR Position: Q1 2026 in Review
Bank of America reduced its NovoCure (NVCR) stake by 50% in Q1 2026, selling an estimated $2.16M and leaving 170,013 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #4167.
Bank of America first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $36.3M in Q2 2021. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Bank of America held 170,013 shares of NovoCure worth $1.85M as of Q1 2026.
- Bank of America sold 172,940 NovoCure shares in Q1 2026, an estimated $2.16M.
- NovoCure made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4167 holding.
- Bank of America first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
- Bank of America's NovoCure position peaked at $36.3M in Q2 2021.
- 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.